Author

G. Glenn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 8 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 9 Assay:proteomics· 6 Research Focus:drug response / drug discovery· 5 Organism:mouse· 4 Organism:non-human primate· 4 Organism:human· 3 Research Focus:cell-cell communication· 1

Frequent Co-Authors

G. Smith· 7 shared J.-H. Tian· 7 shared M. J. Massare· 6 shared N. Patel· 6 shared A. D. Portnoff· 5 shared B. Zhou· 5 shared M. Guebre-Xabier· 5 shared S. Maciejewski· 5 shared

Activity by Year

2020-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

G. Smith

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

J. N. Bhiman, S. I. Richardson, B. E. Lambson, P. Kgagudi, N. Mzindle, H. Kaldine, C. Crowther, G. Gray, L.-G. Bekker, A. Koen, L. Fairlie, L. Fouche, Q. Bhorat, K. Dheda, M. Tameris, , P. L. Moore

This study evaluates the neutralizing antibody response to NVX-CoV2373 against Omicron sub-lineages after two or three doses, showing improved neutralization with a third dose.

bioRxiv · Jul 14, 2022 · PreprintImmunology

NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses

C. Rydyznski Moderbacher, C. Kim, J. Mateus, J. Plested, M. Zhu, S. Cloney-Clark, D. Weiskopf, A. Sette, L. Fries, G. Glenn, S. Crotty

This study shows NVX-CoV2373 vaccine induces CD4+ and CD8+ T cell responses, with CD4+ T cells correlating with neutralizing antibody titers.

bioRxiv · Apr 8, 2022 · PreprintImmunology

Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants

J. Logue, R. Johnson, N. Patel, B. Zhou, S. Maciejewski, H. Zhou, A. Portnoff, J.-H. Tian, M. McGrath, R. Haupt, S. Weston, H. Hammod, M. Guebre-Xabier, C. Dillen, J. Plested, , M. Frieman

This study evaluates a nanoparticle vaccine against SARS-CoV-2 variants, showing it induces strong immune responses and protection in mice and baboons against multiple variants.

bioRxiv · Jun 8, 2021 · PreprintImmunology

Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and QuadrivalentSeasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant

M. J. Massare, N. Patel, B. Zhou, S. Maciejewski, R. Flores, M. Guebre-Xabier, J.-H. Tian, A. D. Portnoff, L. Fries, V. Shinde, L. R. Ellingsworth, G. Glenn, G. Smith

This paper evaluates a combination vaccine against seasonal influenza and SARS-CoV-2 in animal models, showing it induces protective immune responses and prevents viral replication and disease.

bioRxiv · May 5, 2021 · PreprintImmunology

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

M. J. Gorman, N. Patel, M. Guebre-Xabier, A. Zhu, C. Atyeo, K. Pullen, C. Loos, Y. Goez-Gazi, R. Carrion, J.-H. Tian, D. Yuan, K. Bowman, B. Zhou, S. Maciejewski, M. McGrath, , G. Alter

This study shows that NVX-CoV2373 vaccine induces antibodies with both neutralizing and Fc-effector functions, which together provide maximal protection against SARS-CoV-2 in non-human primates.

bioRxiv · Feb 5, 2021 · PreprintImmunology

Flexible RSV prefusogenic fusion glycoprotein exposes multiple neutralizing epitopes that may collectively contribute to protective immunity

N. Natel, J.-H. Tian, R. Flores, K. Jacobson, M. Walker, A. Portnoff, M. Gueber-Xabier, M. J. Massare, G. Glenn, L. R. Ellingsworth, G. Smith

This study compares the immunogenicity of native prefusogenic RSV F glycoprotein variants in animal models, finding that native F elicits broader neutralizing antibodies targeting multiple epitopes compared to variants with structural modifications.

bioRxiv · Sep 14, 2020Immunology

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

M. Guebre-Xabier, N. Patel, J.-H. Tian, B. Zhou, S. Maciejewski, K. Lam, A. D. Portnoff, M. J. Massare, M. B. Frieman, P. A. Piedra, L. R. Ellingsworth, G. Glenn, G. Smith

This study evaluates the NVX-CoV2373 vaccine in cynomolgus macaques, showing it induces neutralizing antibodies and protects against SARS-CoV-2 infection in upper and lower airways.

bioRxiv · Aug 18, 2020Immunology

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

S. Bangaru, G. Ozorowski, H. L. Turner, A. Antanasijevic, D. Huang, X. Wang, J. L. Torres, J. K. Diedrich, J.-H. Tian, A. D. Portnoff, N. Patel, M. J. Massare, J. R. Yates, D. Nemazee, J. C. Paulson, , A. B. Ward

The paper uses cryo-EM and glycan analysis to study the structure of a full-length SARS-CoV-2 spike protein in a vaccine candidate, revealing its stable prefusion conformation and novel trimer interactions.

bioRxiv · Aug 6, 2020Immunology

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

J.-H. Tian, N. Patel, R. Haupt, H. Zhou, S. Weston, H. Hammond, J. Lague, A. D. Portnoff, J. Norton, M. Guebre-Xabier, B. Zhou, K. Jacobson, S. Maciejewski, R. Khatoon, M. Wisniewska, , G. Smith

This study evaluates the immunogenicity and protective efficacy of the NVX-CoV2373 SARS-CoV-2 vaccine in baboons and mice, showing strong immune responses and protection without enhanced disease.

bioRxiv · Jun 29, 2020Microbiology